Rheumatoid arthritis


Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis

Health Technology Assessment. 2010;14(Suppl. 2):1-10


Connock M, Tubeuf S, Malottki K, Uthman A, Round J, Bayliss S, Meads C, Moore D

For more information about health economic modelling or to request a quote please contact Alex Diamantopoulos at info@symmetron.net



Publications in other disease areas

Atrial fibrillation

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke


Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Idiopathic pulmonary fibrosis

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review


The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Rheumatoid arthritis

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK


Venous thromboembolism

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective